



Sleep Deprivation Selectively Down-Regulates Astrocytic 5-HT_{2B} Receptors and Triggers Depressive-Like Behaviors *via* Stimulating P2X₇ Receptors in Mice

Maosheng Xia^{1,2} · Zexiong Li¹ · Shuai Li¹ · Shanshan Liang¹ · Xiaowei Li¹ · Beina Chen¹ · Manman Zhang¹ · Chengyi Dong² · Alexei Verkhratsky^{1,3} · Dawei Guan⁴ · Baoman Li^{1,5} 

Received: 13 December 2019 / Accepted: 11 February 2020 / Published online: 6 June 2020
© Shanghai Institutes for Biological Sciences, CAS 2020

Abstract Chronic loss of sleep damages health and disturbs the quality of life. Long-lasting sleep deprivation (SD) as well as sleep abnormalities are substantial risk factors for major depressive disorder, although the underlying mechanisms are not clear. Here, we showed that chronic SD in mice promotes a gradual elevation of extracellular ATP, which activates astroglial P2X₇ receptors (P2X₇Rs). Activated P2X₇Rs, in turn, selectively down-regulated the expression of 5-HT_{2B} receptors (5-HT_{2B}Rs) in astrocytes. Stimulation of P2X₇Rs induced by SD selectively suppressed the phosphorylation of AKT and FoxO3a in astrocytes, but not in neurons. The over-expression of FoxO3a in astrocytes inhibited the expression of 5-HT_{2B}Rs. Down-regulation of 5-HT_{2B}Rs instigated by SD suppressed the activation of STAT3 and relieved the inhibition of Ca²⁺-dependent phospholipase A2. This latter

cascade promoted the release of arachidonic acid and prostaglandin E2. The depression-like behaviors induced by SD were alleviated in P2X₇R-KO mice. Our study reveals the mechanism underlying chronic SD-induced depression-like behaviors and suggests 5-HT_{2B}Rs as a key target for exploring therapeutic strategies aimed at the depression evoked by sleep disorders.

Keywords Astrocyte · Sleep deprivation · P2X₇ receptor · 5-HT_{2B} receptor · FoxO3a

Introduction

Good sleep safeguards physical health and the quality of life, and contributes to cognitive and emotional functions. Prolonged sleep deprivation (SD) increases the risk of mood disorders [1] and impairs the regulation of emotions [2]. Our previous studies revealed that chronic SD induces depression-like behaviors *via* stimulating an astroglial inflammatory response. This response is linked to the activation of P2X₇ purinoceptors associated with the activation of the NLRP3 (nucleotide-binding domain and leucine-rich repeat protein-3) inflammasome. We also found that the anti-depressant fluoxetine suppresses the activation of the NLRP3 inflammasome caused by SD *via* astroglial 5-HT_{2B} receptors (5-HT_{2B}Rs) [3, 4]. In this study, we found that the depression-like behaviors induced by SD were improved in P2X₇-receptor knockout mice, and 5-HT_{2B}Rs can be regulated by SD *via* P2X₇Rs. Hence, a potential mechanism linking P2X₇Rs and 5-HT_{2B}Rs is further studied in this work, especially in the context of chronic SD.

Dynamic changes in brain extracellular ATP during the sleep-wake cycle have not been studied extensively.

✉ Alexei Verkhratsky
Alexej.Verkhatsky@manchester.ac.uk

✉ Dawei Guan
dwguan@cmu.edu.cn

✉ Baoman Li
bmli@cmu.edu.cn

¹ Practical Teaching Centre, School of Forensic Medicine, China Medical University, Shenyang 110122, China

² Department of Orthopaedics, The First Hospital, China Medical University, Shenyang 110001, China

³ Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M139PL, UK

⁴ Department of Forensic Pathology, School of Forensic Medicine, China Medical University, Shenyang 110122, China

⁵ Department of Poison Analysis, School of Forensic Medicine, China Medical University, Shenyang 110122, China

Increased ATP release from neurons during wakefulness has nonetheless been suggested to activate P2X₇Rs in neural cells [5]. Functional P2X₇Rs are distributed in the cortex, hippocampus, and retina, and P2X₇Rs interfere with sleep rhythms directly or indirectly through the release of cytokines and neurotransmitters [6]. The expression of P2X₇Rs is up-regulated in people subjected to chronic SD, and this change in expression is linked to the cycling in bipolar disorder [7].

We previously reported that astroglial 5-HT_{2B}Rs are associated with major depressive disorder. These receptors expressed in astrocytes are targets for serotonin-specific reuptake inhibitors [3, 8, 9]. Down-regulation of 5-HT_{2B}Rs leads to a loss of sleep homeostasis in *Drosophila* [10]. We found that leptin enhances the anti-depressive potential of fluoxetine in the context of SD-induced depression-like behaviors by stimulating 5-HT_{2B}Rs in astrocytes with a consequent increase in the phosphorylation of ERK_{1/2} [11]. We also found that 5-HT_{2B}Rs regulate the expression of Ca²⁺-dependent phospholipase A2 (cPLA2) *via* transactivation of epidermal growth factor receptors [8]. In spinal cord astrocytes, the phosphorylation of cPLA2 induced by ATP leads to the rapid release of arachidonic acid (AA) and prostaglandin E2 (PGE2) [12]. However, whether the level of AA or PGE2 in astrocytes is influenced by chronic SD remains unknown.

Ionotropic P2X₇Rs promote NLRP3 inflammasome assembly and trigger the ATP-induced release of mature interleukin (IL)-1 β and IL-18 from astrocytes [4]. Activation of P2X₇Rs is linked to the NLRP3 inflammasome and the induction of depression-like behaviors induced by chronic stress [13]. Furthermore, P2X₇Rs suppress the phosphorylation of AKT (protein kinase B) and ERK (extracellular-regulated kinase) induced by BzATP in microglia [14]. We demonstrated that SD decreases the phosphorylation of AKT, but not that of ERK [4], while activation of AKT phosphorylates the Forkhead transcriptional factor FoxO3a on the Ser253 site (FoxO3a is an attractive candidate for regulating stress responses) [15].

In this study, we dissected how the SD-induced activation of P2X₇Rs regulates the expression of 5-HT_{2B}Rs and the production of AA and PGE2 to reveal the possible mechanism linking chronic SD with mood disorders, including the major depressive disorder.

Materials and Methods

Animals

As in our previous studies [4, 16], C57BL/6, B6.Cg-Tg(Thy1-YFP)HJrs/J, FVB/N-Tg(GFAP-GFP)14Mes/J, and B6.129P2-P2rx7^{tm1Gab}/J (P2X₇R-KO) mice were all

purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Male mice were used at an age of \sim 3 months (\sim 25 g) and were kept in standard housing conditions (22 \pm 1°C; light/dark cycle of 12 h/12 h) with food and water available *ad libitum*. All mice were randomly assigned to different experimental groups using a random number table. All operations were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 8023) and its 1978 revision, and all experimental protocols were approved by the Institutional Animal Care and Use Committee of China Medical University (No. [2019]059).

Materials

Most chemicals, including BzATP [2'(3')-O-(4-benzoyl-benzoyl)adenosine 5'-triphosphate triethylammonium salt], DAPI [4',6-diamidino-2-phenylindole] dihydrochloride], ARL67156 trisodium salt (6-N,N-diethyl- β - γ -dibromomethylene-D-adenosine-5-triphosphate FPL 67156), BW723C86 [α -methyl-5-(2-thienylmethoxy)-1H-indole-3-ethanamine monohydrochloride], and a primary antibody raised against β -actin were from Sigma (St. Louis, MO, USA). Other primary antibodies, Alexa Fluor-conjugated or horseradish peroxidase-conjugated secondary antibodies, were from Merck Millipore (Burlington, MA, USA). Static (6-nitrobenzo[b]thiophene 1,1-dioxide) was supplied by R&D Systems (Minneapolis, MN, USA). Chemicals for the preparation of cell-sorting medium were from Gibco Life Technology Invitrogen (Grand Island, NY, USA).

SD Protocol

As described previously [17], SD was maintained by “gentle handling” according to the standard protocols, gently touching the mouse with a brush to keep it awake in every cage. SD was maintained for 6 h, beginning at 07:00 and ending at 13:00. During SD, the mice had access to food and water *ad libitum*. Animals in the sham group were left undisturbed in a separate room with the same light/dark cycle as the SD group. The mice were exposed to sham conditions or SD stimulation for 3 or 4 weeks.

Microdialysis and ATP Measurements

Mice were anesthetized with ketamine [80 mg/kg, intraperitoneal injection (i.p.)] and xylazine (10 mg/kg, i.p.). As reported previously [18], a guide cannula (CMA 7, CMA Microdialysis, Stockholm, Sweden) was implanted into the right prefrontal cortex (coordinates: anteroposterior 1.75 mm, mediolateral 0.75 mm, dorsoventral 1.5 mm). A microdialysis probe (CMA 7; molecular

weight cut-off, 6,000 Da) was inserted through the cannula 24 h before the start of experiments. All microdialysis samples were collected from 10:00 at 0, 1, 2, 3, and 4 weeks. Artificial cerebrospinal fluid (ACSF) was perfused through the microdialysis probe at 1 μ L/min, and samples were collected 3 h after probe insertion. To minimize the rate of background ATP hydrolysis, each sample collection tube was pre-treated with ARL 67156, and the interstitial fluid ATP levels were measured immediately.

ATP levels were assessed with a luciferin-luciferase-based assay [19, 20] using a commercial ATP assay system with a bioluminescence detection kit (Enliten, Promega, Madison, WI, USA). ATP was measured according to the manufacturer's protocol. In brief, weighed tissue samples were homogenized in 5% trichloroacetic acid and centrifuged at 5,000 rpm in the cold (4°C) for 5 min, then the supernatant was transferred to a fresh tube. A calibration curve was constructed from standard ATP solutions, samples were neutralized with Tris acetate buffer, and the luciferase reagent was used immediately before measurement in the luminometer.

Cell Dissociation and Fluorescence-Activated Cell Sorting (FACS)

B6.Cg-Tg(Thy1-YFP)HJrs/J and FVB/N-Tg(GFAP-GFP)14Mes/J mice were separately used for isolating neurons and astrocytes. A single-cell suspension of the cortex and hippocampus was prepared as previously described [16]. In brief, tissue from 3 mice was pooled for one sample. Wavelengths of 488 nm and 530 nm were used for yellow fluorescent protein (YFP) or green fluorescent protein (GFP) excitation and emission, respectively. YFP⁺ or GFP⁺ cells were sorted and collected, the purity of neuronal or astrocytic populations sorted has been ascertained by detecting mRNA level of cell specific markers as described previously [21]

Primary Culture of Astrocytes

As described previously [16, 22, 23], astrocytes isolated from the cerebral hemispheres of newborn C57BL/6 mice were cultured in Dulbecco's modified Eagle's medium (DMEM) with 7.5 mmol/L glucose. From the third week, dibutyryl cyclic AMP was added to the medium.

Immunohistochemistry

The brain tissue was fixed in 4% paraformaldehyde and cut at 100 μ m. Immunohistochemistry was performed as previously described [16, 24]. In brief, the following primary antibodies were used: mouse anti-5-HT_{2B}R

(1:150), mouse anti-P2X₇ (1:150), chicken anti-NeuN (1:250), rabbit anti-Glt1 (1:200), and rabbit anti-GFAP (1:250). The sections were incubated with Alexa Fluor-conjugated secondary antibodies for 2 h at room temperature (1:250). DAPI (1:2000) was used to stain cell nuclei. Immunofluorescence was imaged under a confocal scanning microscope (DMi8, Leica, Wetzlar, Germany). The background intensity of each image was calculated for cell-free parenchyma in the same field of view and subtracted from the total immunofluorescence intensity. The intensity of 5-HT_{2B}R immunofluorescence from each group was normalized to the intensity in the sham group.

Western Blotting

As described previously [22, 24], the sections were blocked with powdered skim milk and incubated for 2 h with the primary antibodies at room temperature. After washing three times, specific binding was detected with horseradish peroxidase-conjugated secondary antibodies. Staining was visualized with enhanced chemiluminescence (ECL) detection reagents, and images were acquired with an electrophoresis gel imaging analysis system. Band density was measured in Windows Alpha Ease FC 32-bit software (Tanon; Shanghai, China).

Real-Time PCR (RT-PCR)

As described previously [16], total RNA was reverse-transcribed and PCR amplification was performed with a Thermo-cycler. The RNA quantities were normalized by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) before calculating the relative expression of 5-HT_{2B}Rs. Values were first calculated as the ratios of the expression of 5-HT_{2B}Rs to GAPDH, then the values were normalized to the sham group.

Over-Expression of FoxO3a Using Adenoviral Vectors

As described previously [25, 26], replication-defective adenoviral vectors expressing dominant wild-type FoxO3a were designed by TaKaRa Biotechnology (Dalian, China). The wild-type FoxO3a had a hemagglutinin tag at the N-terminus and expressed GFP. Astrocytes were infected with recombinant adenovirus in DMEM for 8 h, after which the medium was replaced by fresh complete culture medium including 10% fetal bovine serum. The infection efficiency was close to 80%, as determined by GFP expression.

Assessment of Arachidonic Acid (AA) Mobilization

As described previously [27], the release of ^3H from astrocytes pre-labelled with [^3H]AA was used to monitor the response to serotonin. Confluent cultures were changed to quiescent medium for 24 h before they were labelled for 4 h with 1 $\mu\text{Ci}/\text{mL}$ [^3H] AA (PerkinElmer Life Sciences, Shanghai, China). The cells were washed once with PBS containing 0.1% free fatty acid albumin and twice with PBS alone. Astrocytes were then incubated at 37°C in fresh Ham's F-12 medium supplemented with 0.1% free fatty acid albumin plus serotonin or PBS. The astrocytes were washed with 5% Triton and scraped off. The radioactivity levels of astrocytes and medium were quantified by scintillation counting. The results were normalized and expressed as a percentage of the mean of basal release.

PGE2 Assays

As described previously [12, 27], PGE2 levels were monitored using an enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI, USA). The assays were run according to the manufacturer's protocols. PGE2 production was evaluated in duplicate, and concentrations were calculated from a standard curve of PGE2 solutions. The sensitivity of the assay allowed detection of up to 15 pg/mL. When necessary, the samples were diluted in assay buffer.

Tail Suspension Test

This is a despair-based behavioral test. Each mouse was suspended by its tail ~ 2 cm from the tip as we previously described [4, 16] and behavior was recorded for 6 min. The duration of immobility was measured by an observer blinded to the treatment groups.

Forced Swimming Test

This is also a despair-based behavioral test. In brief, each mouse was trained to swim for 15 min before the formal measurement. Then the trained mouse was put into a glass cylinder that contained 30 cm deep water ($25 \pm 1^\circ\text{C}$) and left for 6 min. The immobility time was recorded during the last 4 min that followed 2 min of habituation [3, 16].

Sucrose Preference Test

As previously described [3, 16], the sucrose preference test is a reward-based test and a measure of anhedonia. Briefly, after 12 h of food and water deprivation, each mouse was provided with two pre-weighed bottles – one was filled with 2.5% sucrose and the other contained water – and left

for 2 h. The percentage preference was calculated according to the formula: % preference = [sucrose intake/(sucrose + water intake)] \times 100%.

Statistical Analysis

All measurements were performed by an investigator blinded to the experimental conditions. Differences between multiple groups were evaluated by analysis of variance followed by Fisher's least significant difference or a Tukey-Kramer *post hoc* multiple comparison test for unequal replications using SPSS 19.0 (IBM, Armonk, NY, USA) or GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). All statistical data are expressed as the mean \pm SEM; the level of significance was set at $P < 0.05$.

Results

SD Down-Regulates 5-HT_{2B}R Expression in Astrocytes Through P2X₇Rs

The effect of 4 weeks of SD on extracellular ATP levels in the prefrontal cortex was measured by microdialysis, which showed that SD resulted in a gradual increase (Fig. 1A). At the initial point (week 0), the baseline ATP was 326 ± 193.3 pg/mL in the sham group ($n = 6$). During sham treatment for 4 weeks, the levels did not change significantly. However, SD increased the level to 1226 ± 157.1 pg/mL at 1 week, 1670 ± 192.1 pg/mL at 2 weeks, 1922 ± 201.7 pg/mL at 3 weeks, and 2109 ± 178.4 pg/mL at 4 weeks ($n = 6$). Since SD gradually increased the release of ATP for 4 weeks, we chose 3 weeks for the duration of SD in the subsequent experiments.

The expression of 5-HT_{2B}R mRNA in neurons and astrocytes FACS-sorted from Thy1-YFP and GFAP-GFP mice exposed to SD was determined by RT-PCR. The 5-HT_{2B}R mRNA level was significantly suppressed by $70\% \pm 6.8\%$ ($P = 0.0066$, $n = 6$) in astrocytes; however, SD marginally and non-significantly affected the expression of 5-HT_{2B}R in neurons (Fig. 1B). Meanwhile, after SD for 3 weeks, the fluorescence intensity of 5-HT_{2B}R immunoreactivity was significantly decreased by $73\% \pm 5.4\%$ ($P = 0.0001$, $n = 6$) in astrocytes compared with the sham group; there was no difference in the 5-HT_{2B}R expression in neurons between the sham and SD groups (Fig. 1D, E). However, the SD-induced down-regulation of 5-HT_{2B}Rs was completely eliminated in astrocytes from P2X₇R-KO mice (P2X₇R expression in P2X₇R-KO mice was suppressed; Fig. 1C). The fluorescence intensity of 5-HT_{2B}R immunoreactivity in astrocytes




Fig. 1 P2X₇ receptors mediate the selective decrease of 5-HT_{2B}Rs in astrocytes exposed to chronic SD. **A** Levels of extracellular ATP measured by microdialysis in the prefrontal cortex of wild-type mice with or without SD at 0, 1, 2, 3, and 4 weeks. Data are presented as the mean \pm SEM ($*P < 0.05$ vs sham group at the same time point, $**P < 0.05$ vs other groups; $n = 6$). **B** RT-PCR analysis of 5-HT_{2B}R mRNA expression in FACS-sorted cortical neurons and astrocytes, expressed as the 5-HT_{2B}R/GAPDH ratio. **C** Immunolabeling of P2X₇R (green) co-stained with GlT1 (red) and NeuN (blue) in the cortex of wild-type (WT) and P2X₇R-KO mice (scale bar, 20 μ m). **D** Immunolabeled 5-HT_{2B}Rs (green) co-stained with GFAP (red) and NeuN (blue) in frontal cortex from sham (Control) or SD (3 weeks)

was $102\% \pm 10.4\%$ ($n = 6$) of the sham group, while it was $91\% \pm 6.8\%$ ($P = 0.8764$, $n = 6$) of the sham group in neurons (Fig. 1D, E).

The 5-HT_{2B}R mRNA level measured by RT-PCR reflected the protein expression. Compared with the sham group, 5-HT_{2B}R mRNA expression was down-regulated by $80\% \pm 4.4\%$ ($P = 0.004$, $n = 6$) in the SD group of wild-type mice (Fig. 2F). However, SD decreased the expression of 5-HT_{2B}R mRNA only by $6\% \pm 9.2\%$ ($P = 0.6976$, $n = 6$) of the sham group in P2X₇R-KO mice (Fig. 1F).


The SD-related changes in protein expression of 5-HT_{2B}Rs quantified by western blotting were similarly absent in P2X₇R-KO mice (Fig. 1G). SD significantly reduced the expression of 5-HT_{2B}Rs to $32\% \pm 3.3\%$ ($P < 0.0001$, $n = 6$) of the sham group in wild-type mice, while their level in the SD group was $89\% \pm 4.8\%$

($P = 0.3141$, $n = 6$) of the sham group in P2X₇R-KO mice, and there was no difference in the expression of 5-HT_{2B}R in astrocytes from WT sham and P2X₇R-KO mice (Fig. 1H). The above results showed that SD selectively down-regulates the expression of 5-HT_{2B}Rs via P2X₇Rs in astrocytes, but not in neurons.

Involvement of AKT and FoxO3a in the Regulation of 5-HT_{2B}Rs by P2X₇Rs *In Vivo* and *In Vitro*

In wild-type mice exposed to SD, the phosphorylation of AKT (Ser473) was reduced by $58\% \pm 3.3\%$ ($P = 0.0004$, $n = 6$) of controls (Fig. 2A), and the phosphorylation of FoxO3a (Ser253) was decreased by $61\% \pm 5.4\%$ ($P < 0.0001$, $n = 6$) compared with controls (Fig. 2B). On the contrary, in P2X₇R-KO mice exposed to SD, the

Fig. 2 Signaling cascades involved in the regulation of 5HT_{2B}R expression. **A, B** The ratios of p-AKT to AKT (60 kDa) (**A**), and p-FoxO3a to FoxO3a (97 kDa) (**B**) in wild-type (WT) and P2X₇R-KO mice in the sham (Control) and SD (3 weeks) groups. **C, D** The levels of p-AKT/AKT (**C**) and p-FoxO3a/FoxO3a (**D**) in sorted neurons and astrocytes from Thy1-YFP and GFAP-GFP mice with or without SD (3 weeks). Data are presented as the mean \pm SEM (* $P < 0.05$ vs sham group; $n = 6$).



phosphorylation of AKT was $116\% \pm 16.4\%$ ($P = 0.2720$, $n = 6$) of controls (Fig. 2A), while the level of p-FoxO3a was $123\% \pm 12.3\%$ ($P = 0.4503$, $n = 6$) of controls (Fig. 2B); there was no significant difference between the control and SD groups.

We used SD Thy1-YFP and GFAP-GFP transgenic mice to measure the levels of p-AKT and p-FoxO3a in the FACS-sorted neurons and astrocytes. SD decreased the phosphorylation of AKT in astrocytes by $57\% \pm 4.7\%$ ($P = 0.0003$, $n = 6$) of controls, while there was no difference between the control and SD groups in neurons

(Fig. 2C). Similarly, SD suppressed the phosphorylation of FoxO3a by $69\% \pm 5.2\%$ ($P = 0.0011$, $n = 6$) in astrocytes compared with controls, while no changes were found in neurons (Fig. 2D). *In vivo*, SD selectively decreased the phosphorylation of AKT and FoxO3a in astrocytes by stimulating P2X₇Rs.


In primary cultured astrocytes, we used the P2X₇R agonist BzATP to simulate the effects of ATP on P2X₇Rs induced by SD. To probe the mechanism by which P2X₇Rs regulate the expression of 5-HT_{2B}Rs in these astrocytes, we used siRNA duplex to interfere with the mRNA of P2X₇Rs.

This manipulation decreased the level of P2X₇Rs by 88% ± 3.4% of controls (Fig. 3A). To determine the effect of transcription factor FoxO3a on the expression of 5-HT_{2B}Rs, we over-expressed FoxO3a in primary cultured astrocytes (Fig. 3B).

Administration of BzATP reduced the phosphorylation of AKT by 66% ± 4.3% ($P < 0.0001$, $n = 6$) of the PBS

control group in astrocytes (Fig. 3C). In contrast, after treatment with siRNA, this effect was abolished, as there was no significant difference between the PBS and BzATP groups (Fig. 3C). Phosphorylation of FoxO3a was decreased by 52% ± 4.1% ($P < 0.0001$, $n = 6$) in the BzATP group compared with the PBS control (Fig. 3D). After 3 days of P2X₇R siRNA treatment, the

Fig. 3 Role of P2X₇Rs in regulating the expression of 5-HT_{2B}Rs *in vivo*. **A** qPCR analysis of P2X₇R mRNA expression in negative control primary cultured astrocytes and those treated with P2X₇R siRNA duplex for 3 days, expressed as the expression ratio normalized to the control group. Data are presented as the mean ± SEM ($*P < 0.05$ vs control group; $n = 6$). **B** Immunohistochemical staining of FoxO3a (green) co-stained with DAPI (blue) and GFAP (red) in astrocytes with or without recombinant adenovirus infection for 3 days (scale bars, 20 μm). **C, D** Ratios of p-AKT to AKT (**C**) and p-FoxO3a to FoxO3a (**D**) in primary cultured astrocytes pre-treated with P2X₇R siRNA duplex for 3 days. Data represent the mean ± SEM ($*P < 0.05$ vs control group; $n = 6$). **E** Ratio of 5-HT_{2B}R to β-actin protein expression in primary cultured astrocytes pre-treated with P2X₇R siRNA duplex or over-expressing FoxO3a with recombinant adenovirus for 3 days. Data are presented as the mean ± SEM ($*P < 0.05$ vs PBS group, $**P < 0.01$ vs other groups; $n = 6$).



phosphorylation of FoxO3a treated with BzATP recovered to $94\% \pm 7.7\%$ ($P = 0.6482$, $n = 6$) of the PBS group (Fig. 3D). In astrocytes, BzATP reduced the expression of 5-HT_{2B}Rs by $69\% \pm 3.2\%$ ($P < 0.0001$, $n = 6$) of the PBS group (Fig. 3E). This effect was eliminated after siRNA treatment: in the presence of BzATP, the level of 5-HT_{2B}R decreased insignificantly, to $91\% \pm 7.3\%$ ($P = 0.5739$, $n = 6$) of the PBS group (Fig. 3E). After over-expressing FoxO3a, the basic level of 5-HT_{2B}Rs was reduced by $62\% \pm 4.7\%$ ($P = 0.0007$, $n = 6$) compared with the PBS group without over-expression, but BzATP did not change the expression of 5-HT_{2B}Rs (Fig. 3E). *In vitro*, stimulating P2X₇Rs down-regulated the expression of astrocytic 5-HT_{2B}Rs by suppressing the phosphorylation of AKT and FoxO3a.

Effects of P2X₇Rs on the Phosphorylation of STAT3 and cPLA2 are Associated with 5-HT_{2B}Rs *In Vivo* and *In Vitro*

Exposure of mice to SD decreased the phosphorylation of STAT3 by $66\% \pm 5.4\%$ ($P = 0.0004$, $n = 6$) of controls; however, this effect was abolished in P2X₇R-KO mice – the level of p-AKT in the SD group was $97\% \pm 8.9\%$ ($P = 0.8371$, $n = 6$) of controls (Fig. 4A). In contrast, SD had the opposite effect on the activation of cPLA2; the phosphorylation of cPLA2 in mice exposed to SD increased by $67\% \pm 8.7\%$ ($P = 0.0088$, $n = 6$) compared with controls (Fig. 4B). This effect was absent from P2X₇R-KO mice in which SD did not stimulate the activation of cPLA2 (Fig. 4B).

In experiments *in vitro*, we used the 5-HT_{2B}R agonist BW723C86 (BW) to stimulate 5-HT_{2B}Rs. In cultured astrocytes, BW induced the phosphorylation of STAT3 by $73\% \pm 10.7\%$ ($P = 0.0008$, $n = 6$) of controls, and the 5-HT_{2B}R-specific antagonist SB204741 totally suppressed the phosphorylation of STAT3 stimulated by BW (Fig. 4C). Treatment with BW decreased the level of p-cPLA2 by $57\% \pm 3.9\%$ ($P < 0.0001$, $n = 6$) of controls, while the irreversible STAT3 activation inhibitor Stattic elevated the phosphorylation of cPLA2 to $96\% \pm 8.7\%$ ($P = 0.7767$, $n = 6$) of controls; there was no difference between the control and Stattic groups (Fig. 4D).

BW decreased the level of AA by $31\% \pm 7.1\%$ ($P = 0.0216$, $n = 6$) and that of PGE2 by $57\% \pm 3.3\%$ ($P = 0.0007$, $n = 6$) compared with the control group (Fig. 4E, F). Exposure to Stattic increased the release of AA and PGE2 reduced by BW to $105\% \pm 12.2\%$ ($P = 0.7458$, $n = 6$) and $116\% \pm 12.7\%$ ($P = 0.3743$, $n = 6$) of control (Fig. 4E, F). These results demonstrated that SD increases the release of AA and PGE2 by increasing the activation of cPLA2 mediated by P2X₇Rs and STAT3.

Effects of P2X₇Rs on the Depression-Like Behaviors Induced by SD


We monitored depressive-like behaviors in P2X₇R-KO mice (Fig. 5). There was no difference in body weight between the control and SD groups of wild-type and P2X₇R-KO mice (Fig. 5A). In the sucrose preference test, SD decreased the percentage uptake of sucrose water by $47\% \pm 5.3\%$ ($P = 0.0019$, $n = 6$) compared with controls in WT mice (Fig. 5B). The anhedonia induced by SD was abolished in P2X₇R-KO mice; the uptake of sucrose water was $89\% \pm 4.7\%$ ($P = 0.3201$, $n = 6$) of controls (Fig. 5B). In the tail suspension test, the immobility time of the SD group was prolonged to $155\% \pm 15.1\%$ of controls ($P = 0.0070$, $n = 6$), while this time was reduced to $107\% \pm 11.2\%$ ($P = 0.6480$, $n = 6$) of controls in P2X₇R-KO mice (Fig. 5C). Similarly, the immobility time in the forced-swimming test was increased by $106\% \pm 11.7\%$ ($P = 0.0049$, $n = 6$) of the control group, and the time was increased only to $113\% \pm 9.5\%$ ($P = 0.6330$, $n = 6$) of the sham group in P2X₇R-KO mice (Fig. 5D). The depression-like behaviors induced by prolonged SD were dependent on P2X₇Rs.

Discussion

Here we demonstrate that chronic SD gradually increases the extracellular levels of ATP that subsequently stimulate P2X₇Rs, which decrease the astroglial expression of 5-HT_{2B}Rs. This effect does not occur in neurons. Stimulation of P2X₇Rs triggered by SD suppresses the expression of 5-HT_{2B}Rs by inhibiting the phosphorylation of AKT (Ser473) and FoxO3a (Ser253) in astrocytes. Dephosphorylated FoxO3a translocates into the nucleus [15, 28], where it down-regulates the expression of 5-HT_{2B}Rs in astrocytes. The downregulation of 5-HT_{2B}Rs induced by SD is caused by the decrease in activation of STAT3 which inhibits the activation of cPLA2. As a result, chronic SD indirectly stimulates the phosphorylation of cPLA2 by down-regulating the expression of 5-HT_{2B}Rs in astrocytes. This increased activation of cPLA2 stimulates the release of AA and PGE2, which may be linked to the depression-like behaviors (Fig. 6).

The mechanisms of sleep are complex and sleep impairments have numerous negative impacts. In this study, we initially found that chronic SD gradually increased the extracellular concentration of ATP in the prefrontal cortex, while the depression-like behaviors induced by SD were mediated by P2X₇Rs, a subtype of ionotropic purinoceptor [29]. This contrasts with some reports showing that decreased ATP levels accompany depression-like behaviors in mice [18]. Other reports,


Fig. 4 P2X₇Rs regulate the 5-HT_{2B}R-dependent activation of STAT3 and cPLA2. **A, B** The ratios of p-STAT3 to STAT3 (86 kDa) (**A**) and p-cPLA2 to cPLA2 (95 kDa) (**B**) in wild-type (WT) and P2X₇R-KO sham (Control) and SD (3 weeks) groups. **C–F** The ratios of p-STAT3 to STAT3 (**C**) and p-cPLA2 to cPLA2 (**D**), and the release of ³H-AA (**E**) and PGE2 (**F**) from primary cultured astrocytes pre-treated with SB204741 (selective 5-HT_{2B}R antagonist) or Stattic (STAT3 inhibitor) for 30 min, then treated with the specific 5-HT_{2B}R agonist BW723C86 (BW) for 1 h. Data represent the mean ± SEM (**P* < 0.05 vs other groups; *n* = 6).



however, corroborate our findings. For example, psychological stress has been reported to promote depression-like behaviors by increasing the release of ATP from astrocytes and stimulating neuroinflammation [30]. The sleep-

regulating signal triggered by extracellular ATP activates glial P2X₇Rs, which stimulate the release of pro-inflammatory cytokines such as TNF- α and IL-1 β [31], and potentiate neuroinflammation. Indeed, we found that the

Fig. 5 The depression-like behaviors induced by SD are eliminated in P2X₇R-KO mice. **A–D** Body weight (**A**), percentage sucrose preference (**B**), and immobility time in the tail suspension test (**C**) and forced-swimming test (**D**) in wild-type (WT) and P2X₇R-KO mice in the sham (Control) and SD (3 weeks) groups. Values are expressed as the mean \pm SEM (* $P < 0.05$ vs other groups; $n = 6$).



activation of NLRP3 inflammasomes induced by prolonged SD was abolished in P2X₇R-KO mice, and the effects of prolonged SD on neuronal apoptosis were also eliminated by inhibiting the activation of inflammasomes [4].

In previous reports, we showed that astroglial 5-HT_{2B}Rs are the key target of selective serotonin reuptake inhibitors. In particular, fluoxetine directly stimulates astroglial 5-HT_{2B}Rs, which thus mediate the anti-depressant action [8, 9, 23, 32]. The elevation of 5-HT_{2B}R expression by leptin enhances the positive effects of fluoxetine on the depressive-like behaviors induced by chronic SD [3]. In the present study, prolonged SD selectively blocked the expression of 5-HT_{2B}Rs by activating P2X₇Rs in astrocytes (Fig. 1). The activation of P2X₇Rs induced by SD decreased the phosphorylation of AKT selectively in astrocytes, but did not change the level of p-AKT in neurons (Fig. 2A, C). Likewise, BzATP induced the dephosphorylation of AKT in primary cultured astrocytes (Fig. 3C); the same effect of BzATP has also been reported in microglia [33]. However, BzATP does not change the activation of AKT in granule neurons [34]. Activated AKT phosphorylates FoxO3a at Ser253 in the cytoplasm [15, 28]. In contrast, dephosphorylation of FOXO3a causes its translocation from the cytoplasm into the nucleus, which triggers downstream gene expression [15, 28]. We demonstrated that stimulation of astrocytic P2X₇Rs suppressed the phosphorylation of FoxO3a *in vivo* and *in vitro* (Figs. 2B, D, 3D), which promoted the translocation of FoxO3a into the nucleus and inhibited the expression of 5-HT_{2B}Rs. Over-expression of

FoxO3a in the nucleus decreased the level of 5-HT_{2B}Rs (Fig. 3E), while FoxO3a-KO mice presented evident anti-depressive-like behaviors [15].

We previously reported that chronic SD decreases the phosphorylation of STAT3 in astrocytes [3]. In this study, we showed that this decrease was caused by the reduced expression of 5-HT_{2B}Rs, because the activation of 5-HT_{2B}Rs by an agonist (BW) increased the phosphorylation of STAT3 in astrocytes (Fig. 4C). Although treatment with ATP increases the activation of cPLA2 in spinal cord astrocytes, pre-treatment with leptin eliminates the phosphorylation of cPLA2 induced by ATP *via* increasing the level of p-STAT3 and caveolin-1, which in turn reduces the release of AA and PGE2 [24]. cPLA2 selectively acts on AA containing acyl chains *in vitro* [35] and cPLA2 is a crucial enzyme in AA-derived eicosanoid production [36]. PGE2 is metabolized from AA by cyclooxygenase (COX) and is an important regulator of chronic inflammation [37]. Prolonged SD induced the phosphorylation of cPLA2 and increased the release of AA and PGE2 *via* regulating 5-HT_{2B}Rs in astrocytes (Fig. 4).

Both cPLA2 and COX-2 have been associated with major depressive disorder [38, 39], the level of PGE2 increases in depression, and the use of COX-2 inhibitors as antidepressants has been suggested [40]. In this study, chronic SD induced the activation of cPLA2 which triggered the production of AA and PGE2 *via* P2X₇Rs (Fig. 4), while the depression-like behaviors induced by long-term SD were abolished in P2X₇R-KO mice (Fig. 5).




Fig. 6 The expression and function of 5-HT_{2B} receptors are selectively decreased by SD through P2X₇ receptors in astrocytes. Prolonged SD stimulates P2X₇Rs via ATP, the activated P2X₇Rs suppress the phosphorylation of AKT and FoxO3a in the cytoplasm, and the dephosphorylated FoxO3a accumulates in the nucleus of astrocytes. The increased FoxO3a down-regulates the expression of 5-HT_{2B}Rs, and the phosphorylation of STAT3 is also decreased, which relieves the inhibition of the phosphorylation of cPLA2. The activated cPLA2 promotes the release of AA and PGE2, eventually causing depression-like behaviors.

In summary, our study revealed the mechanism underlying the depressive-like behaviors induced by chronic SD, and revealed that the decreased expression of 5-HT_{2B}Rs induced by SD is mediated through P2X₇Rs, the latter being stimulated by increased levels of extracellular ATP. The down-regulated 5-HT_{2B}Rs dephosphorylated STAT3 thus relieving the inhibitory effect of STAT3 on the activation of cPLA2. Our results suggest that selective agonists of 5-HT_{2B}Rs or reagents that up-regulate the expression of 5-HT_{2B}Rs may be considered as therapeutic agents for preventing depression triggered by sleep disorders.

Acknowledgements This work was supported by the National Natural Science Foundation of China (81871852, 81200935, 81671862, and 81871529), Liaoning Revitalization Talents Program (XLYC1807137), the Scientific Research Foundation for Overseas Scholars of the Education Ministry of China (20151098), and the Natural Science Foundation of Liaoning Province, China (20170541030).

Conflict of interest The authors report no financial interests or potential conflicts of interest.

References

- Alvaro PK, Roberts RM, Harris JK, Bruni O. The direction of the relationship between symptoms of insomnia and psychiatric disorders in adolescents. *J Affect Disord* 2017, 207: 167–174.
- Goldstein AN, Walker MP. The role of sleep in emotional brain function. *Annu Rev Clin Psychol* 2014, 10: 679–708.
- Li X, Liang S, Li Z, Li S, Xia M, Verkhatsky A, *et al.* Leptin increases expression of 5-HT_{2B} receptors in astrocytes thus enhancing action of fluoxetine on the depressive behavior induced by sleep deprivation. *Front Psychiatry* 2018, 9: 734.
- Xia M, Li X, Yang L, Ren J, Sun G, Qi S, *et al.* The ameliorative effect of fluoxetine on neuroinflammation induced by sleep deprivation. *J Neurochem* 2018, 146: 63–75.
- Chennaoui M, Arnal PJ, Drogou C, Leger D, Sauvet F, Gomez-Merino D. Leukocyte expression of type 1 and type 2 purinergic receptors and pro-inflammatory cytokines during total sleep deprivation and/or sleep extension in healthy subjects. *Front Neurosci* 2017, 11: 240.
- Illes P, Verkhatsky A, Burnstock G, Franke H. P2X receptors and their roles in astroglia in the central and peripheral nervous system. *Neuroscientist* 2012, 18: 422–438.
- Backlund L, Lavebratt C, Frisén L, Nikamo P, Hukic Sudic D, Träskman-Bendz L, *et al.* P2RX7: expression responds to sleep deprivation and associates with rapid cycling in bipolar disorder type 1. *PLoS One* 2012, 7: e43057.
- Li B, Zhang S, Li M, Hertz L, Peng L. Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT_{2B}-induced, transactivation-mediated ERK1/2 phosphorylation. *Psychopharmacology (Berl)* 2009, 207: 1–12.
- Peng L, Song D, Li B, Verkhatsky A. Astroglial 5-HT_{2B} receptor in mood disorders. *Expert Rev Neurother* 2018, 30: 1–8.
- Qian Y, Cao Y, Deng B, Yang G, Li J, Xu R, *et al.* Sleep homeostasis regulated by 5HT_{2b} receptor in a small subset of neurons in the dorsal fan-shaped body of drosophila. *Elife* 2017, 6: e26519.
- Li B, Zhang S, Li M, Hertz L, Peng L. Serotonin increases ERK1/2 phosphorylation in astrocytes by stimulation of 5-HT_{2B} and 5-HT_{2C} receptors. *Neurochem Int* 2010, 57: 432–439.
- Xia M, Zhu Y. Signaling pathways of ATP-induced PGE2 release in spinal cord astrocytes are EGFR transactivation-dependent. *Glia* 2011, 59: 664–674.
- Yue N, Huang H, Zhu X, Han Q, Wang Y, Li B, *et al.* Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors. *J Neuroinflammation* 2017, 14: 102.
- Kim JE, Ko AR, Hyun HW, Min SJ, Kang TC. P2RX7-MAPK1/2-SP1 axis inhibits MTOR independent HSPB1-mediated astroglial autophagy. *Cell Death Dis* 2018, 9: 546.
- Polter A, Yang S, Zmijewska AA, van Groen T, Paik JH, Depinho RA, *et al.* Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. *Biol Psychiatry* 2009; 65, 150–159.
- Xia M, Yang L, Sun G, Qi S, Li B. Mechanism of depression as a risk factor in the development of Alzheimer's disease: the function of AQP4 and the glymphatic system. *Psychopharmacology (Berl)* 2017, 234: 365–379.
- Franken P, Dijk DJ, Tobler I, Borbély AA. Sleep deprivation in rats: effects on EEG power spectra, vigilance states, and cortical temperature. *Am J Physiol* 1991, 261: R198–R208.

18. Cao X, Li LP, Wang Q, Wu Q, Hu HH, Zhang M, *et al.* Astrocyte-derived ATP modulates depressive-like behaviors. *Nat Med* 2013, 19: 773–777.
19. Lundin A, Thore A. Analytical information obtainable by evaluation of the time course of firefly bioluminescence in the assay of ATP. *Anal Biochem* 1975, 66: 47–63.
20. McElroy WD, DeLuca MA. Firefly and bacterial luminescence: basic science and applications. *J Appl Biochem* 1983, 5: 197–209.
21. Fu H, Li B, Hertz L, Peng L. Contributions in astrocytes of SMIT1/2 and HMIT to myo-inositol uptake at different concentrations and pH. *Neurochem Int* 2012, 61: 187–194.
22. Li B, Zhang S, Zhang H, Hertz L, Peng L. Fluoxetine affects GluK2 editing, glutamate-evoked Ca(2+) influx and extracellular signal-regulated kinase phosphorylation in mouse astrocytes. *J Psychiatry Neurosci* 2011, 36: 322–338.
23. Li B, Zhang S, Zhang H, Nu W, Cai L, Hertz L, *et al.* Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. *Psychopharmacology (Berl)* 2008, 201: 443–458.
24. Li B, Qi S, Sun G, Yang L, Han J, Zhu Y, *et al.* Leptin suppresses adenosine triphosphate-induced impairment of spinal cord astrocytes. *J Neurosci Res* 2016, 94: 924–935.
25. Ren J, Li X, Sun G, Li S, Liang S, Li Z, *et al.* Protective effect of leptin-mediated caveolin-1 expression on neurons after spinal cord injury. *Cell Calcium* 2018, 76: 122–128.
26. Xia M, Zhu Y. FOXO3a involvement in the release of TNF- α stimulated by ATP in spinal cord astrocytes. *J Mol Neurosci* 2013, 51: 792–804.
27. Xia M, Zhu Y. Fibronectin enhances spinal cord astrocyte proliferation by elevating P2Y1 receptor expression. *J Neurosci Res* 2014, 92: 1078–1090.
28. Li D, Luo L, Xu M, Wu J, Chen L, Li J, *et al.* AMPK activates FOXO3a and promotes neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia. *Brain Res Bull* 2017, 132: 1–9.
29. Zhou J, Zhang X, Zhou Y, Wu B, Tan ZY. Up-regulation of P2X7 Receptors Contributes to Spinal Microglial Activation and the Development of Pain Induced by BmK-I. *Neurosci Bull* 2019, 35: 624–636.
30. Iwata M, Ota KT, Li XY, Sakaue F, Li N, Duthel S, *et al.* Psychological stress activates the inflammasome *via* release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor. *Biol Psychiatry* 2016, 80: 12–22.
31. Krueger JM, Huang YH, Rector DM, Buysse DJ. Sleep: a synchrony of cell activity-driven small network states. *Eur J Neurosci* 2013, 38: 2199–2209.
32. Peng L, Gu L, Li B, Hertz L. Fluoxetine and all other SSRIs are 5-HT2B agonists - Importance for their therapeutic effects. *Curr Neuropharmacol* 2014, 12: 365–379.
33. He Y, Taylor N, Fourgeaud L, Bhattacharya A. The role of microglial P2X7: modulation of cell death and cytokine release. *J Neuroinflammation* 2017, 14: 135.
34. Ortega F, Pérez-Sen R, Delicado EG, Miras-Portugal MT. P2X7 nucleotide receptor is coupled to GSK-3 inhibition and neuroprotection in cerebellar granule neurons. *Neurotox Res* 2009, 15: 193–204.
35. Sundler R, Winstedt D, Wijkander J. Acyl-chain selectivity of the 85-kDa phospholipase A2 and of the release process in intact macrophages. *Biochem J* 1994, 15: 455–458.
36. Dennis EA, Cao J, Hsu Y, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. *Chem Rev* 2011, 111: 6130–6185.
37. Kalinski P. Regulation of immune responses by prostaglandin E2. *J Immunol* 2012, 188: 21–28.
38. Gałecki P, Florkowski A, Bieńkiewicz M, Szemraj J. Functional polymorphism of cyclooxygenase-2 gene (G-765C) in depressive patients. *Neuropsychobiology* 2010, 62: 116–120.
39. Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, Lee KU, *et al.* BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. *Neuropsychobiology* 2004, 49: 185–188.
40. Müller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. *Curr Opin Investig Drugs* 2010, 11: 31–42.